Sartorius Stedim Biotech (DIM.PA) Stock Price

Sartorius Stedim Biotech Price

Euronext·CLOSED
179.60EUR-2.00 (-1.11 %)
Market closed

Revenue has compounded at 9.6% per year over the past 19 years to 2.97 B EUR. Earnings per share have grown at 15.2% per year over the last 16 years. Sartorius Stedim Biotech's net margin stands at 9.0%, down from 14.4% several years earlier. Sartorius Stedim Biotech currently offers a dividend yield of about 0.38%. The payout ratio is around 25% of earnings. The dividend has grown at 7.0% per year over the past 19 years. Analysts set a median price target of 244.80 EUR, implying 36.3% above the current price. Of 19 analysts, 14 rate the stock a buy — an overall Buy consensus. The stock trades about 19% above its 52-week low.

Sartorius Stedim Biotech stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Sartorius Stedim Biotech over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Sartorius Stedim Biotech stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Sartorius Stedim Biotech's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Sartorius Stedim Biotech Stock Price History
DateSartorius Stedim Biotech Price
8/19/2026179.60 EUR
8/17/2026181.60 EUR
8/14/2026185.50 EUR
8/13/2026181.20 EUR
8/12/2026179.40 EUR
8/11/2026180.40 EUR
8/10/2026181.40 EUR
8/7/2026177.90 EUR
8/6/2026174.30 EUR
8/5/2026173.80 EUR
8/4/2026172.20 EUR
7/31/2026166.70 EUR
7/30/2026172.60 EUR
7/29/2026171.20 EUR
7/28/2026162.60 EUR
7/27/2026162.70 EUR
7/24/2026167.30 EUR
7/23/2026161.30 EUR
7/22/2026175.30 EUR
7/21/2026166.60 EUR
7/20/2026180.20 EUR
7/17/2026187.70 EUR
7/16/2026187.40 EUR
7/15/2026189.00 EUR
7/14/2026188.50 EUR
7/13/2026185.30 EUR
7/10/2026183.30 EUR
7/9/2026179.60 EUR
7/8/2026177.30 EUR
7/7/2026179.30 EUR
7/6/2026179.40 EUR
7/3/2026179.90 EUR
7/2/2026182.10 EUR
7/1/2026178.20 EUR
6/30/2026181.60 EUR
6/29/2026178.30 EUR
6/26/2026175.20 EUR
6/25/2026177.00 EUR
6/24/2026169.20 EUR
6/23/2026163.20 EUR
6/22/2026161.90 EUR
6/19/2026164.70 EUR
6/18/2026164.40 EUR
6/17/2026176.90 EUR
6/16/2026178.30 EUR
6/15/2026179.40 EUR
6/12/2026178.40 EUR
6/11/2026179.30 EUR
6/10/2026179.20 EUR
6/9/2026177.70 EUR
6/8/2026177.00 EUR
6/5/2026184.60 EUR
6/4/2026182.30 EUR
6/3/2026175.50 EUR
6/2/2026181.00 EUR
6/1/2026176.90 EUR
5/29/2026179.40 EUR
5/28/2026169.60 EUR
5/27/2026173.90 EUR
5/26/2026171.20 EUR
5/25/2026172.20 EUR
5/22/2026173.50 EUR
5/21/2026168.30 EUR
5/20/2026161.20 EUR
5/19/2026161.40 EUR
5/18/2026158.50 EUR
5/15/2026155.90 EUR
5/14/2026163.10 EUR
5/13/2026160.80 EUR
5/12/2026160.20 EUR
5/11/2026164.30 EUR
5/8/2026163.60 EUR
5/7/2026164.90 EUR
5/6/2026167.20 EUR
5/5/2026162.40 EUR
5/4/2026155.50 EUR
4/30/2026156.70 EUR
4/29/2026151.50 EUR
4/28/2026156.80 EUR
4/27/2026159.70 EUR
4/24/2026162.30 EUR
4/23/2026157.90 EUR
4/22/2026184.00 EUR
4/21/2026188.50 EUR
4/20/2026186.70 EUR
4/17/2026188.70 EUR
4/16/2026182.20 EUR
4/15/2026183.70 EUR
4/14/2026180.80 EUR
4/13/2026173.90 EUR
4/10/2026170.30 EUR
4/9/2026168.90 EUR
4/8/2026173.20 EUR
4/7/2026169.30 EUR
4/2/2026167.36 EUR
3/27/2026165.03 EUR
3/26/2026166.94 EUR
3/25/2026169.34 EUR
3/24/2026165.27 EUR
3/23/2026162.79 EUR
3/20/2026168.59 EUR
3/19/2026171.26 EUR
3/17/2026170.94 EUR
3/16/2026160.18 EUR
3/13/2026161.13 EUR
3/12/2026163.20 EUR
3/11/2026163.83 EUR
3/10/2026166.48 EUR
3/9/2026159.86 EUR
3/6/2026165.61 EUR
3/5/2026171.09 EUR
2/27/2026183.40 EUR
2/26/2026181.54 EUR
2/25/2026182.84 EUR
2/23/2026178.17 EUR
2/20/2026182.50 EUR
2/19/2026175.98 EUR
2/18/2026174.16 EUR
2/16/2026170.98 EUR
2/13/2026174.95 EUR
2/12/2026171.47 EUR
2/11/2026175.78 EUR
2/10/2026178.52 EUR
2/9/2026178.23 EUR
2/6/2026176.59 EUR
2/5/2026181.64 EUR
2/4/2026181.20 EUR
2/3/2026188.00 EUR
2/2/2026187.24 EUR
1/30/2026189.03 EUR
1/29/2026191.56 EUR
1/28/2026196.76 EUR
1/27/2026204.80 EUR
1/26/2026206.99 EUR
1/23/2026206.31 EUR
1/22/2026209.61 EUR
1/21/2026204.00 EUR
1/19/2026207.80 EUR
1/17/2026213.16 EUR
1/16/2026212.96 EUR
1/14/2026211.23 EUR
1/13/2026214.56 EUR
1/12/2026214.55 EUR
1/10/2026215.66 EUR
1/8/2026219.86 EUR
1/7/2026222.23 EUR
1/6/2026220.09 EUR
1/5/2026214.12 EUR
1/2/2026208.41 EUR
12/31/2025208.22 EUR
12/30/2025208.05 EUR
12/29/2025208.01 EUR
12/24/2025205.80 EUR
12/23/2025207.29 EUR
12/22/2025205.11 EUR
12/19/2025204.41 EUR
12/18/2025203.90 EUR
12/17/2025203.86 EUR
12/16/2025208.25 EUR
12/15/2025207.54 EUR
12/12/2025205.60 EUR
12/11/2025207.42 EUR
12/10/2025209.53 EUR
12/9/2025208.24 EUR
12/8/2025213.51 EUR
12/5/2025213.58 EUR
12/4/2025214.01 EUR
12/3/2025214.47 EUR
12/2/2025207.54 EUR
11/28/2025206.49 EUR
11/27/2025201.91 EUR
11/25/2025199.83 EUR
11/24/2025194.07 EUR
11/21/2025186.91 EUR
11/20/2025186.64 EUR
11/19/2025185.56 EUR
11/18/2025185.70 EUR
11/17/2025189.69 EUR
11/14/2025191.24 EUR
11/12/2025194.00 EUR
11/11/2025191.34 EUR
11/10/2025188.73 EUR
11/8/2025188.29 EUR
11/7/2025188.55 EUR
11/6/2025190.64 EUR
11/5/2025194.88 EUR
11/4/2025199.37 EUR
11/3/2025201.80 EUR
10/31/2025208.69 EUR
10/30/2025207.01 EUR
10/29/2025208.89 EUR
10/28/2025210.38 EUR
10/27/2025211.04 EUR
10/24/2025210.00 EUR
10/23/2025210.66 EUR
10/22/2025212.02 EUR
10/21/2025211.33 EUR
10/20/2025206.72 EUR
10/17/2025203.97 EUR
10/16/2025204.88 EUR
10/15/2025185.98 EUR
10/14/2025182.79 EUR
10/13/2025186.45 EUR
10/10/2025188.03 EUR
10/9/2025190.91 EUR
10/8/2025192.91 EUR
10/7/2025197.49 EUR
10/6/2025197.50 EUR
10/3/2025195.72 EUR
10/2/2025190.24 EUR
10/1/2025184.51 EUR
9/30/2025172.05 EUR
9/29/2025171.05 EUR
9/26/2025171.55 EUR
9/25/2025174.50 EUR
9/24/2025184.31 EUR
9/23/2025187.04 EUR
9/22/2025185.40 EUR
9/19/2025185.01 EUR
9/18/2025182.31 EUR
9/17/2025174.94 EUR
9/16/2025175.74 EUR
9/15/2025173.40 EUR
9/12/2025169.65 EUR
9/11/2025171.94 EUR
9/10/2025175.56 EUR
9/9/2025175.34 EUR
9/8/2025173.93 EUR
9/5/2025173.41 EUR
9/4/2025171.05 EUR
9/3/2025174.52 EUR
9/2/2025174.11 EUR
9/1/2025177.72 EUR
8/29/2025175.07 EUR
8/28/2025174.98 EUR
8/27/2025174.50 EUR
8/26/2025177.49 EUR
8/25/2025175.68 EUR
8/22/2025178.06 EUR
8/21/2025177.32 EUR
8/20/2025179.40 EUR
8/19/2025177.77 EUR
Access this data via the Eulerpool API
Get Free API Key

Sartorius Stedim Biotech Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
2.78 B EUR
484.50 M EUR
309.70 M EUR
Jan 1, 2024
2.78 B EUR
370.60 M EUR
175.10 M EUR
Jan 1, 2025
2.97 B EUR
549.00 M EUR
265.60 M EUR
Jan 1, 2026 (e)
3.13 B EUR
671.66 M EUR
485.10 M EUR
Jan 1, 2027 (e)
3.47 B EUR
742.29 M EUR
578.76 M EUR
Jan 1, 2028 (e)
3.86 B EUR
821.76 M EUR
692.92 M EUR
Jan 1, 2029 (e)
4.28 B EUR
912.66 M EUR
817.00 M EUR
Jan 1, 2030 (e)
4.80 B EUR
1.02 B EUR
979.13 M EUR

Sartorius Stedim Biotech Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 19, 2026, 3:40 PM
 
REVENUEB EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB EUR
EBITB EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
DIV.EUR
DIV. GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
0.881.051.081.211.441.912.893.492.782.782.973.133.473.864.284.80
29.4318.892.8512.1218.8132.6451.1021.00-20.530.186.735.3310.8811.2811.0512.12
51.0250.0551.2551.9051.9452.4653.8152.0344.4343.3845.3345.3345.3345.3345.3345.33
0.450.530.550.630.751.001.551.821.231.211.351.421.571.751.942.18
0.180.230.220.300.330.470.911.110.480.370.550.670.740.820.911.02
20.8121.4120.4424.7523.0624.6631.6031.7917.4413.3118.5021.4721.4121.2921.3021.31
117.00153.00161.00208.00234.00335.00414.00876.00309.00175.00265.00485.00578.00692.00816.00979.00
62.5030.775.2329.1912.5043.1623.58111.59-64.73-43.3751.4383.0219.1819.7217.9219.98
1.302.000.420.460.570.340.682.521.440.690.690.690.690.69––
8.3353.85-79.009.5223.91-40.35100.00270.59-42.86-52.08––––––
92.0893.1693.2591.4892.8692.1892.3192.1792.1796.7897.3097.3097.3097.3097.3097.30
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Sartorius Stedim Biotech generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Sartorius Stedim Biotech retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Sartorius Stedim Biotech's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Sartorius Stedim Biotech has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Sartorius Stedim Biotech's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Sartorius Stedim Biotech stock margins

The Sartorius Stedim Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Sartorius Stedim Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Sartorius Stedim Biotech.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
53.79 %
31.61 %
14.35 %
Jan 1, 2022
52.03 %
31.80 %
25.08 %
Jan 1, 2023
44.44 %
17.46 %
11.16 %
Jan 1, 2024
43.41 %
13.33 %
6.30 %
Jan 1, 2025
45.33 %
18.50 %
8.95 %
Jan 1, 2026 (e)
45.33 %
21.49 %
15.52 %
Jan 1, 2027 (e)
45.33 %
21.42 %
16.70 %
Jan 1, 2028 (e)
45.33 %
21.31 %
17.97 %

Sartorius Stedim Biotech Stock Revenue, EBIT, Earnings per Share

The Sartorius Stedim Biotech earnings per share therefore indicates how much revenue Sartorius Stedim Biotech has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
31.27 EUR
9.89 EUR
4.49 EUR
Jan 1, 2022
37.90 EUR
12.05 EUR
9.51 EUR
Jan 1, 2023
30.11 EUR
5.26 EUR
3.36 EUR
Jan 1, 2024
28.73 EUR
3.83 EUR
1.81 EUR
Jan 1, 2025
30.50 EUR
5.64 EUR
2.73 EUR
Jan 1, 2026 (e)
32.13 EUR
6.90 EUR
4.99 EUR
Jan 1, 2027 (e)
35.62 EUR
7.63 EUR
5.95 EUR
Jan 1, 2028 (e)
39.63 EUR
8.45 EUR
7.12 EUR

Sartorius Stedim Biotech business model & stock analysis

Sartorius Stedim Biotech SA is a company specializing in the development, manufacturing, and marketing of products and services for the biopharmaceutical industry. It was formed in 2007 through the merger of two companies, Sartorius and Stedim Biotech, and is headquartered in Aubagne, France. The company has a history dating back to 1870 when Florenz Sartorius, a mechanic, founded a precision scale factory in Göttingen, Germany. Over the years, Sartorius became a leading provider of laboratory scales and equipment worldwide. In 1951, the company was renamed Sartorius AG and expanded into filtration technology. Stedim Biotech, on the other hand, was founded in 1957 as a manufacturer of plastic products and is based in Aubagne, France. It has since become a leading provider of products and services for the biopharmaceutical industry. Today, Sartorius Stedim Biotech SA operates in four business segments: bioprocess systems, laboratory equipment, services, and specialized products. Its bioprocess systems segment includes products and solutions for biopharmaceutical production such as fermenters, bioreactors, cryogenic storage tanks, and filtration systems. The laboratory equipment segment offers a wide range of lab products including scales, pipettes, and analysis devices. The services segment includes consulting, training, and technical services for the biopharmaceutical industry. Lastly, the specialized products segment provides a broad range of products for specific applications, such as disposable syringes for medication administration. Sartorius Stedim Biotech SA has developed a wide range of products for the biopharmaceutical industry, including fermenters and bioreactors for the production of biological drugs, filtration systems for protein purification and cell culture media, disposable syringes for medication administration, and laboratory equipment for sample analysis. The company's business model is to offer a comprehensive range of products and services for the biopharmaceutical industry. It focuses on high-quality and innovative products and services, as well as providing consultation and support to its customers in solving challenges in biopharmaceutical production. Overall, Sartorius Stedim Biotech SA is a leading provider of products and services for the biopharmaceutical industry. Its broad product range and consultancy and support services make it an important partner for the biopharmaceutical industry in the production of biological drugs.

Sartorius Stedim Biotech SWOT Analysis

Strengths

With innovative product portfolio, Sartorius Stedim Biotech SA demonstrates technological superiority and a competitive edge in the market. The company's strong focus on research and development enables it to deliver cutting-edge solutions to its customers, ensuring customer satisfaction and loyalty.

Sartorius Stedim Biotech SA boasts a vast global footprint through its extensive distribution network. This enables the company to effectively reach various markets worldwide, expanding its customer base and revenue streams.

Weaknesses

Despite its strong presence in the market, Sartorius Stedim Biotech SA faces challenges related to limited diversification of its product offerings. This puts the company at risk of losing market share in case of technological advancements or changes in customer preferences.

Sartorius Stedim Biotech SA's heavy reliance on external suppliers for key components of its products poses a potential vulnerability, as disruptions in the supply chain may impact production and delivery timelines.

Opportunities

The rising demand for biopharmaceuticals presents a significant opportunity for Sartorius Stedim Biotech SA to capitalize on. The company can leverage its expertise in bioprocessing technologies to develop and offer specialized solutions that cater to this growing market.

Expansion into emerging markets, such as Asia and Latin America, can provide Sartorius Stedim Biotech SA with new growth avenues. These markets offer untapped potential and can serve as a source of revenue diversification for the company.

Threats

Intense competition in the biotech industry poses a threat to Sartorius Stedim Biotech SA. The presence of established players and new entrants constantly vying for market share may lead to price wars and margin pressures.

Changing regulatory landscape and compliance requirements pose challenges for Sartorius Stedim Biotech SA. Ensuring adherence to evolving regulations and standards can be costly and time-consuming, potentially affecting the company's operations and profitability.

Sartorius Stedim Biotech Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Sartorius Stedim Biotech historical P/E ratio, EBIT multiple, and P/S ratio

Sartorius Stedim Biotech annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Sartorius Stedim Biotech shares outstanding

The number of shares of Sartorius Stedim Biotech was 97.3 M in 2025. This indicates how many shares Sartorius Stedim Biotech is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
92.31 M Stocks
Jan 1, 2022
92.17 M Stocks
Jan 1, 2023
92.17 M Stocks
Jan 1, 2024
96.78 M Stocks
Jan 1, 2025
97.30 M Stocks
Jan 1, 2026 (e)
97.30 M Stocks
Jan 1, 2027 (e)
97.30 M Stocks
Jan 1, 2028 (e)
97.30 M Stocks

Sartorius Stedim Biotech stock splits

In Sartorius Stedim Biotech's history, there have been no stock splits.

Sartorius Stedim Biotech Dividend History

30 years of dividend payments

YearAnnual DividendYoY ChangePayments
20260.69EURYTD—1×
Mar 31, 20260.69EUR 0.0%1/1
20250.69EUR 0.0%1×
Apr 2, 20250.69EUR 0.0%1/1
20240.69EUR↓ 52.1%1×
20231.44EUR↓ 42.9%1×
20222.52EUR↑ 270.6%2×
20210.68EUR↑ 100.0%1×
20200.34EUR↓ 40.4%1×
20190.57EUR↑ 23.9%1×
20180.46EUR↑ 9.5%1×
20170.42EUR↓ 79.0%1×

Sartorius Stedim Biotech dividend history and estimates

In 2025, Sartorius Stedim Biotech paid a dividend amounting to 0.69 EUR. Dividend means that Sartorius Stedim Biotech distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Details
Date
Dividend
Dividend (Estimate)
Special dividend
Jan 1, 2021
0.68 EUR
0.00 EUR
0.00 EUR
Jan 1, 2022
2.52 EUR
0.00 EUR
0.00 EUR
Jan 1, 2023
1.44 EUR
0.00 EUR
0.00 EUR
Jan 1, 2024
0.69 EUR
0.00 EUR
0.00 EUR
Jan 1, 2025
0.69 EUR
0.00 EUR
0.00 EUR
Jan 1, 2026
0.69 EUR
0.00 EUR
0.00 EUR
Jan 1, 2027 (e)
0.00 EUR
0.69 EUR
0.00 EUR
Jan 1, 2028 (e)
0.00 EUR
0.69 EUR
0.00 EUR

Sartorius Stedim Biotech dividend payout ratio

In 2025, Sartorius Stedim Biotech had a payout ratio of 25.28%. The payout ratio indicates the percentage of the company's profits that Sartorius Stedim Biotech distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
15.15 %
Jan 1, 2022
26.51 %
Jan 1, 2023
42.85 %
Jan 1, 2024
38.14 %
Jan 1, 2025
25.28 %
Jan 1, 2026 (e)
13.84 %
Jan 1, 2027 (e)
11.63 %
Jan 1, 2028 (e)
9.75 %

Current Sartorius Stedim Biotech forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
2.24 %
Buy
73.68 % (14)
Hold
26.32 % (5)
Sell
0.00 % (0)
12M Price Target
244.80
Last Price
181.60
Currency
EUR
12M Return Potential
34.80 %
LTM Return
0 %

Sartorius Stedim Biotech Analyst Rating Actions

DateFirmActionRating
10/1/2021
Societe Generale
Societe Generale
DowngradeBuyHold

Sartorius Stedim Biotech Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
10/19/20223.05EUR-911.31 MEUR-2022 Q3
7/21/20223.27EUR-887.82 MEUR-2022 Q2
4/21/20222.79EUR-791.72 MEUR-2022 Q1
1/27/20221.83EUR-759.56 MEUR-2021 Q4
10/20/20211.85EUR-707.15 MEUR-2021 Q3
7/21/20211.57EUR-673.82 MEUR-2021 Q2
4/21/20211.46EUR-587.69 MEUR-2021 Q1
1/27/20211.09EUR-492.47 MEUR-2020 Q4
10/20/20200.95EUR-459.11 MEUR-2020 Q3
7/21/20200.91EUR-456.85 MEUR-2020 Q2

EESG©

Eulerpool ESG Scorecard© for the Sartorius Stedim Biotech stock

80/100
99
Environment
99
Social
41
Governance
E

Environment

20
Scope 1 - Direct Emissions13,712
Scope 2 - Indirect emissions from purchased energy40,780
Scope 3 - Indirect emissions within the value chain527,796
Total CO₂ emissions54,492
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees39.249
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Sartorius Stedim Biotech shareholder structure

% Name
71.52499%
Sartorius AG
Sartorius AG
0.95189%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
0.91330%
Comgest S.A.
Comgest S.A.
0.88720%
T. Rowe Price Associates, Inc.
T. Rowe Price Associates, Inc.
0.73982%
Fidelity Management & Research Company LLC
Fidelity Management & Research Company LLC
0.55472%
Invesco Advisers, Inc.
Invesco Advisers, Inc.
...

Sartorius Stedim Biotech Beneficial Ownership Filings (SEC 13D/G)

Free Float
28.5%
Float Shares
-
Shares Outstanding
-

Sartorius Stedim Biotech Executives and Management Board

10 members · avg. age 60 · 60 % women

RF

Dr. Rene Faber (49)

Chief Executive Officer, Executive Director · since 2019

1.21 M EUR

Management

PK

Ms. Petra Kirchhoff (56)

Head of Corporate Communications and Investor Relations · since 2020

–

Board of Directors

JK

Dr. Joachim Kreuzburg (59)

Executive Chairman of Board · since 2007

364,000.00 EUR
PB

Ms. Pascale Boissel (58)

Non-Executive Independent Director

93,000.00 EUR
AG

Ms. Anne-Marie Graffin (63)

Lead Non-Executive Independent Director

91,000.00 EUR
LK

Dr. Lothar Kappich (68)

Non-Executive Director

84,000.00 EUR
SD

Ms. Susan Dexter (69)

Non-Executive Independent Director

84,000.00 EUR
RF

Mrs. Romaine Fernandes (55)

Non-Executive Director, Employee Representative

–

Sartorius Stedim Biotech Supply Chain

Sartorius Stedim Biotech Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
11 companies
#Nameβ 1YTrend
1
Sartorius Vz
Supplier·Customer·DE
0.92
0.93
0.80
0.95
0.93
0.96
—
2
Lonza Group
Customer·Life Sciences Tools & Services·CH
0.37
0.95
0.82
0.92
0.92
0.90
0.64
3
Waters
Supplier·Customer·Life Sciences Tools & Services·US
-0.13
-0.03
0.19
0.76
0.85
0.90
0.79
4
Roche Holding
Customer·Pharmaceuticals·CH
0.09
0.92
0.53
0.41
0.17
0.57
0.12
5
Pfizer
Customer·Pharmaceuticals·US
-0.33
0.88
0.58
0.55
-0.11
0.56
-0.06
#Nameβ 1YTrend
1
Amgen
Customer·Biotechnology·US
0.01
0.57
0.23
-0.69
-0.50
-0.48
-0.34
2
GlaxoSmithKline
Customer·Pharmaceuticals·GB
0.18
-0.47
-0.02
-0.40
-0.46
-0.08
—
3
Sanofi
Customer·Pharmaceuticals·FR
-0.05
0.09
-0.13
-0.72
-0.69
-0.04
-0.52
4
Merck & Co
Customer·Pharmaceuticals·US
0.13
0.06
-0.01
-0.37
-0.27
0.06
-0.17
5
Regeneron Pharmaceuticals
Customer·Biotechnology·US
0.35
0.87
0.38
-0.17
0
0.24
0.00

Frequently asked questions about Sartorius Stedim Biotech

The business model of Sartorius Stedim Biotech SA revolves around providing innovative solutions for the biopharmaceutical industry. The company specializes in the development, production, and sale of a wide range of equipment and services used in biotech research and manufacturing processes. Sartorius Stedim Biotech SA offers state-of-the-art technologies including filtration systems, bioreactors, fluid management systems, and single-use products. Through its comprehensive product portfolio, the company strives to support biopharmaceutical companies in the efficient and safe production of life-saving drugs and therapies. With a focus on quality, reliability, and sustainability, Sartorius Stedim Biotech SA aims to be a trusted partner for the global biotechnology industry.

Sartorius Stedim Biotech SA is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Sartorius Stedim Biotech SA in the market include industry leaders such as Thermo Fisher Scientific Inc., Danaher Corporation, and Merck KGaA. These companies are actively engaged in the biotechnology and life sciences sector, offering a wide range of products and solutions. With its strong presence and innovative technologies, Sartorius Stedim Biotech SA competes with these major players by providing advanced bioprocessing solutions, lab instruments, and consumables. Continuous technological advancements and strategic collaborations enable Sartorius Stedim Biotech SA to maintain its competitive edge in the global market.

Sartorius Stedim Biotech SA is a leading biotechnology company with a rich history and background. Founded in 1978, the company specializes in providing innovative solutions and high-quality products for the biopharmaceutical industry. With headquarters in France, it operates globally, serving customers in over 110 countries. Sartorius Stedim Biotech SA has consistently expanded its portfolio, offering a wide range of products, including bioreactors, purification, and filtration systems, as well as high-tech laboratory equipment. The company's commitment to research and development has paved the way for advancements in bioprocessing technologies. With a focus on quality, reliability, and customer satisfaction, Sartorius Stedim Biotech SA continues to be a trusted partner for biopharmaceutical companies worldwide.

Sartorius Stedim Biotech SA has achieved significant milestones throughout its history. The company has consistently delivered innovative solutions in the biotech industry. Some notable milestones include the development of cutting-edge bioprocess equipment and consumables, leading to advancements in bioprocessing efficiency. Sartorius Stedim Biotech SA has also expanded its global presence through strategic acquisitions and partnerships, strengthening its position as a key player in the biopharmaceutical market. The company's commitment to quality and continuous improvement has garnered recognition and numerous awards. With a focus on customer satisfaction and technological advancements, Sartorius Stedim Biotech SA continues to shape the future of bioprocessing.

Sartorius Stedim Biotech SA is primarily present in various countries and regions across the globe. The company has a significant presence in Europe, particularly in countries like Germany, France, and the United Kingdom. It also operates in the Americas, including the United States and Canada. Additionally, Sartorius Stedim Biotech SA has a strong presence in the Asia-Pacific region, with operations in countries such as China, Japan, and Australia.

Sartorius Stedim Biotech SA represents a strong commitment to values and a distinctive corporate philosophy. The company focuses on providing innovative solutions and high-quality products in the field of bioprocessing. Sartorius Stedim Biotech values integrity, customer orientation, and sustainability in its business operations. It strives to foster strong partnerships, both with its customers and employees, to deliver outstanding results. By adhering to its corporate philosophy, Sartorius Stedim Biotech aims to contribute to the advancement of biotechnology and improve the overall well-being.

Analysts currently set an average price target of 241.58 EUR for the Sartorius Stedim Biotech stock (median: 244.80 EUR), implying +33.0 % versus the latest price. The consensus is based on 19 analyst ratings.

Sartorius Stedim Biotech Analyst Price Targets 2026

19 analysts currently rate the Sartorius Stedim Biotech stock: 14 recommend buying, 5 holding and 0 selling. For 2026, analysts expect Sartorius Stedim Biotech to generate revenue of 3.13 B EUR and earnings per share of 4.99 EUR.

Sartorius Stedim Biotech Analyst Price Targets 2026

The Sartorius Stedim Biotech share (DIM.PA) is listed on 9 stock exchanges, including: XETRA (56S1.DE), Frankfurt (56S1.F), München (56S1.MU), Düsseldorf (56S1.DU), London (0RG8.L), Wien (DIM.VI), Paris (DIM.PA).

Sartorius Stedim Biotech SA is a leading provider of equipment and services for the biopharmaceutical industry. The company is headquartered in Aubagne, France, and employs over 6,300 people worldwide. The business model of Sartorius Stedim Biotech consists of three main divisions: process solutions, filtration technologies, and services. In the process solutions division, the company offers a wide range of bioreactors, validation solutions, and other systems for the production of biopharmaceuticals. These solutions include both disposable and reusable systems, allowing customers to optimize their production processes and reduce costs. The filtration technologies division of Sartorius Stedim Biotech offers specialized membranes, filters, and filter capsules that can be used in biopharmaceutical manufacturing. The company offers a variety of products specifically designed for the filtration of biomolecules and other sensitive substances. The services division of Sartorius Stedim Biotech offers a variety of services to support customers in implementing their biopharmaceutical production systems. The company provides comprehensive support for system validation, on-site training, and technical assistance. In addition to these three main divisions, the company also offers a wide range of other products and services. Examples include cell sorting systems, thermocoagulometers, and bioanalysis tools. The business model of Sartorius Stedim Biotech is based on offering customers a comprehensive range of products and services to support them in the production of biopharmaceuticals. The company has focused on the biopharmaceutical industry due to the growing demand for new biopharmaceutical products and the high demand for equipment and services specifically developed for this field. Sartorius Stedim Biotech has built its business based on innovation and research. The company invests a significant portion of its revenue in research and development to expand its product range and develop innovative solutions for the biopharmaceutical industry. Overall, Sartorius Stedim Biotech has built a successful business model based on comprehensive products and services for the biopharmaceutical industry. The company has focused on areas with high demand and growth potential and has continuously improved its products and services through extensive investments in research and development.

The expected revenue of Sartorius Stedim Biotech is 3.13 B EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Sartorius Stedim Biotech is 485.10 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Sartorius Stedim Biotech is currently 36.02. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Sartorius Stedim Biotech stock.

The price-to-sales ratio (P/S) of Sartorius Stedim Biotech is currently 5.59. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Sartorius Stedim Biotech stock.

The Eulerpool Quality Score for Sartorius Stedim Biotech is 5/10.

The ISIN of Sartorius Stedim Biotech is FR0013154002. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Sartorius Stedim Biotech is A2AJKS. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Sartorius Stedim Biotech is DIM.PA. The ticker symbol is used to trade Sartorius Stedim Biotech shares on the stock exchange.

Over the past 12 months, Sartorius Stedim Biotech paid a dividend of 0.69 EUR . This corresponds to a dividend yield of about 0.38 %. For the coming 12 months, Sartorius Stedim Biotech is expected to pay a dividend of 0.69 EUR.

The current dividend yield of Sartorius Stedim Biotech is 0.38 %.

Sartorius Stedim Biotech pays a dividend, distributed in the months of , , , .

Sartorius Stedim Biotech paid dividends every year for the past 26 years.

For the upcoming 12 months, dividends amounting to 0.69 EUR are expected. This corresponds to a dividend yield of 0.38 %.

Sartorius Stedim Biotech is assigned to the 'Health' sector.

To receive the latest dividend of Sartorius Stedim Biotech from amounting to 0.69 EUR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Sartorius Stedim Biotech distributed 0.69 EUR as dividends.

The dividends of Sartorius Stedim Biotech are distributed in EUR.

All fundamentals and in-depth analysis of Sartorius Stedim Biotech

Our stock analysis for Sartorius Stedim Biotech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sartorius Stedim Biotech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Sartorius Stedim Biotech Stock
Sartorius Stedim Biotech Revenue→
Sartorius Stedim Biotech Stock
Sartorius Stedim Biotech Net Income→
Sartorius Stedim Biotech Stock
Sartorius Stedim Biotech P/E→
Sartorius Stedim Biotech Stock
Sartorius Stedim Biotech P/S→
Sartorius Stedim Biotech Stock
Sartorius Stedim Biotech EBIT→
Sartorius Stedim Biotech Stock
Sartorius Stedim Biotech Dividend→
Sartorius Stedim Biotech Stock
Sartorius Stedim Biotech Directors Dealings→
Sartorius Stedim Biotech Stock
Sartorius Stedim Biotech Stocks→
Sartorius Stedim Biotech Stock
Sartorius Stedim Biotech Market capitalization→
Sartorius Stedim Biotech Stock
Sartorius Stedim Biotech Debt→
Sartorius Stedim Biotech Stock
Sartorius Stedim Biotech Liabilities→
Sartorius Stedim Biotech Stock
Sartorius Stedim Biotech Equity→
Sartorius Stedim Biotech Stock
Sartorius Stedim Biotech AAQS→
Sartorius Stedim Biotech Stock
Sartorius Stedim Biotech Employees→
Sartorius Stedim Biotech Stock
Sartorius Stedim Biotech ROE→
Sartorius Stedim Biotech Stock
Sartorius Stedim Biotech ROA→
Sartorius Stedim Biotech Stock
Sartorius Stedim Biotech ROCE→
Sartorius Stedim Biotech Stock
Sartorius Stedim Biotech News→
Sartorius Stedim Biotech Stock
Sartorius Stedim Biotech Analyst Price Targets→

Health Stocks

Sativa Growth InternationalSartoriusSaudi Chemical Holding Company SJSCSareum HoldingsSaudi Pharmaceutical Industries and Medical Appliances Corp SPIMACO ADDWAEIH SJSCSarepta TherapeuticsSavaraSarana Meditama Metropolitan Tbk PTSavior LifetecSANUWAVE HealthSawai Group Holdings CoSanthera Pharmaceuticals HoldingAll Stocks A–Z →